Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
Antiviral Res
; 108: 79-87, 2014 Aug.
Article
en En
| MEDLINE
| ID: mdl-24893207
ABSTRACT
Hepatitis C virus (HCV) is a causative agent of chronic hepatitis. Although the standard therapy for HCV-infected patients consists of pegylated interferon plus ribavirin, this treatment is associated with serious side effects and high costs, and fails in some patients infected with specific HCV genotypes. To address this problem, we are developing small-molecule inhibitors of cyclin-dependent kinases (CDKs) as novel anti-HCV drug candidates. Previous data showed that HCV replication is inhibited by retinoblastoma protein, which is itself inactivated by CDK-mediated phosphorylation. Here, we report that CDK inhibitors suppress HCV replication in vitro and in vivo, and that CDK4 is required for efficient HCV replication. These findings shed light on the development of novel anti-HCV drugs that target host factors.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Antivirales
/
Replicación Viral
/
Hepacivirus
/
Quinasas Ciclina-Dependientes
/
Inhibidores Enzimáticos
Límite:
Humans
Idioma:
En
Revista:
Antiviral Res
Año:
2014
Tipo del documento:
Article